50 patents
Utility
Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
9 Jan 24
The invention relates generally to multispecific polypeptides having constrained CD3 binding.
Brendan P. Eckelman, Michael D. Kaplan, Katelyn M. Willis, Quinn Deveraux, John C. Timmer
Filed: 11 Apr 18
Utility
Multivalent and Multispecific 41BB-Binding Proteins
28 Dec 23
This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF).
Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
Filed: 16 Dec 22
Utility
SIGLEC-8 Binding Proteins and Uses Thereof
21 Dec 23
Provided herein are Siglec-8 binding proteins, and methods of using Siglec-8 binding proteins to modulate the biological activity of Siglec-8.
Tony Dung-Ling Yao, Andrew M. Eckles, Jacob J. Gano, Bryan Becklund, Brendan P. Eckelman
Filed: 28 Jul 23
Utility
Serpin fusion polypeptides and methods of use thereof
28 Nov 23
This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a (whey acidic protein) WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide.
Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
Filed: 22 Jun 20
Utility
Effective Dosage of Recombinant Serpin-fc Fusion Protein for Use In a Method of Treating Aat Deficiency In a Subject
16 Nov 23
The present application relates to an effective dosage of an aqueous solution comprising an engineered AAT-Fc fusion dimeric protein for use in a method of treating or alleviating a symptom associated with aberrant serine protease activity in a subject in need thereof.
James KALABUS, Sharvari BHAGWAT
Filed: 16 May 23
Utility
CD28 Single Domain Antibodies and Multivalent and Multispecific Constructs Thereof
2 Nov 23
Provided herein are binding polypeptides that specifically bind CD28.
John C. TIMMER, Rutger H. JACKSON, Katelyn M. WILLIS, William S. CRAGO, Michael D. KAPLAN, Brendan P. ECKELMAN
Filed: 28 Jan 21
Utility
Canine PD-1-Binding Polypeptides and Uses Thereof
19 Oct 23
Provided herein are VHH-containing polypeptides that bind canine PD-1.
Rajay Pandit, John C. Timmer, Brendan P. Eckelman, Quinn Deveraux
Filed: 3 May 21
Utility
CD33-Binding Polypeptides and Uses Thereof
5 Oct 23
Provided herein are VHH-containing polypeptides that bind CD33.
Kyle S. Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
Filed: 16 Dec 22
Utility
Multispecific Polypeptide Constructs Having Constrained CD3 Binding and Related Methods and Uses
21 Sep 23
The invention relates generally to multispecific polypeptides having constrained CD3 binding.
Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, John C. TIMMER
Filed: 6 Jun 23
Utility
Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
27 Jul 23
Provided herein are polypeptide comprising a modified IL-2, wherein the modified IL-2 has reduced affinity for the IL-2 receptor relative to wild type IL-2.
John C. Timmer, Florian Sulzmaier, Katelyn M. Willis, Bryan R. Becklund, Brendan P. Eckelman
Filed: 1 Jul 21
Utility
OX40-Binding Polypeptides and Uses Thereof
27 Apr 23
Provided herein are VHH-containing polypeptides that bind OX40.
John C. Timmer, William Crago, Kyle Jones, Katelyn Willis, Florian Sulzmaier, Bryan Becklund, Brendan P. Eckelman
Filed: 8 Aug 22
Utility
CD123-Binding Polypeptides and Uses Thereof
2 Mar 23
Provided herein are VHH-containing polypeptides that bind CD123.
Chelsie Macedo, Kyle Jones, William Crago, Andrew Hollands, Milton Ma, John C. Timmer, Brendan P. Eckelman
Filed: 1 Aug 22
Utility
PDL1-binding proteins
31 Jan 23
This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF).
Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
Filed: 15 Oct 19
Utility
CD33-binding polypeptides and uses thereof
24 Jan 23
Provided herein are VHH-containing polypeptides that bind CD33.
Kyle S. Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
Filed: 1 May 20
Utility
CLL-1 Targeted Immunotherapies
13 Oct 22
The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
JORDAN JARJOUR, MARK POGSON, WAI-HANG LEUNG, LUCAS RASCON, ANGELICA SANABRIA, JOHN C. TIMMER, BRENDAN P. ECKELMAN
Filed: 7 May 20
Utility
CD33 Targeted Immunotherapies
13 Oct 22
The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
JORDAN JARJOUR, MARK POGSON, WAI-HANG LEUNG, KYLE JONES, WILLIAM CRAGO, ANGELICA SANABRIA, ANDREW HOLLANDS, JACOB GANO, MILTON MA, JOHN C. TIMMER, BRENDAN P. ECKELMAN
Filed: 7 May 20
Utility
Serpin Fusion Polypeptides and Methods of Use Thereof
13 Oct 22
This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide.
Brendan P. ECKELMAN, John C. TIMMER, Quinn DEVERAUX
Filed: 10 May 21
Utility
CD123 Targeted Immunotherapies
6 Oct 22
The present disclosure provides improved CD123 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
JORDAN JARJOUR, MARK POGSON, WAI-HANG LEUNG, CHELSIE MACEDO, KYLE JONES, WILLIAM CRAGO, ANDREW HOLLANDS, MILTON MA, JOHN C. TIMMER, BRENDAN P. ECKELMAN
Filed: 7 May 20
Utility
OX40-binding polypeptides and uses thereof
20 Sep 22
Provided herein are VHH-containing polypeptides that bind OX40.
John C. Timmer, William Crago, Kyle Jones, Katelyn Willis, Florian Sulzmaier, Bryan Becklund, Brendan P. Eckelman
Filed: 12 Aug 19
Utility
CD123-binding polypeptides and uses thereof
6 Sep 22
Provided herein are VHH-containing polypeptides that bind CD123.
Chelsie Macedo, Kyle Jones, William Crago, Andrew Hollands, Milton Ma, John C. Timmer, Brendan P. Eckelman
Filed: 1 May 20